ClinicalTrials.gg
RecruitingNCT07848828ARCHUpdated Nov 2, 2026

Autonomic and Renal Contributions to Hypertension With ADT

A Phase 4 interventional study of Gonadotropin Releasing Hormone Agonists (GNRH) and Androgen receptor (AR) inhibitor in Androgen Deprivation Therapy, Prostate Cancer and Hypertension, sponsored by Virginia Commonwealth University. Recruiting at 1 site in United States. Open to male participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Virginia Commonwealth University · Phase 4, Interventional, and Basic science

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 2, 2026Enrollment updatedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Prostatic Neoplasms by Virginia Commonwealth University — 4 open to participants now, 4 under way, none of them phase 3. Prostatic Neoplasms · Virginia Commonwealth University.

Planned enrollment
2nd of 12
60 · median 28
Started
2026
with 1 other
Phase 4
Only one
of the 14
Registered
14th of 14
by date

Among the 14 studies in Prostatic Neoplasms by Virginia Commonwealth University, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 4, and was the 14th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 14 studies in Prostatic Neoplasms by Virginia Commonwealth University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 40 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Prostatic Neoplasms by Virginia Commonwealth University, or all of them as a file.
02

Study summary

This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure. The results from this study will help us understand the ways in which ADT contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors.

03

Conditions studied

  • Androgen Deprivation Therapy
  • Prostate Cancer
  • Hypertension
  • Autonomic Dysfunction
  • Renal Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 40+ years;
  • resting blood pressure \<140/90 mmHg;
  • fasted blood glucose \<126 mg/dL;
  • testosterone ≥400 ng/dL;
  • sedentary to recreationally active;
  • nonsmokers;
  • healthy as determined by medical history, physical exam, blood and urine chemistries and resting and exercise during a physician supervised graded exercise treadmill test OR recent diagnosis of non- prostate cancer with plans to undergo androgen deprivation therapy;
  • PSA \<4.00 ng/dL if in the non-cancer group;
  • Gleason Score ≤7 if in the prostate cancer group;
  • no use of medications that might influence cardiovascular function (e.g., antihypertensives, lipid-lowering medications);
  • willing and able to be on GnRHagonist and AR inhibitor;
  • not taking antioxidant vitamins, , or anti-inflammatory medications, or willing to stop use for four weeks prior to the start of the study;
  • not using exogenous sex hormones for at least one year

Exclusion criteria

Exclusion Criteria:

  • -acute liver disease;
  • chronic kidney disease, serum creatinine >1.3 mg/dL, macroalbuminuria >300 mg/g of proteinuria
  • pre-existing or active cardiac, renal or hepatic disease, epilepsy or other seizure disorder;
  • diabetes, active or chronic infection, disease that affects the nervous system;
  • Gleason Score ≥8;
  • thyroid dysfunction, defined as ultrasensitive TSH \<0.5 or >5.0 mU/L, volunteers with abnormal TSH values will be re-considered for participation after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement;
  • tobacco use within the previous 12 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Prostate Cancer

    Men undergoing androgen deprivation therapy via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for the treatment of prostate cancer

    Drug: Gonadotropin Releasing Hormone Agonists (GNRH) · Drug: Androgen receptor (AR) inhibitor

  • Active comparator
    Healthy + ADT

    Healthy men undergoing gonadal suppression via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for 9 weeks

    Drug: Gonadotropin Releasing Hormone Agonists (GNRH) · Drug: Androgen receptor (AR) inhibitor

  • Placebo comparator
    Healthy + Placebo

    Healthy men undergoing placebo for 9 weeks.

    Drug: Placebo

Interventions

  • 8 weeks of GnRH agonist

    Also known as: Leuprolide

  • DrugAndrogen receptor (AR) inhibitor

    2 weeks of AR inhibitor

    Also known as: Bicalutamide, Flutamide

  • DrugPlacebo

    Placebo tablet and injection

06

What researchers measure

Primary outcomes

  1. Change in cardiovagal baroreflex sensitivity

    The change in cardiovagal baroreflex sensitivity will be assessed via the sequence method

    Time frame: Before and after 9 weeks of ADT or placebo

  2. Change in blood pressure reactivity to the cold pressor test

    The change in systolic blood pressure will be assessed from quiet rest to sympathetic activation using the cold pressor test

    Time frame: Before and after 9 weeks of androgen deprivation therapy or placebo

  3. Change in exercise pressor reflex

    The change in systolic blood pressure will be assessed from quiet rest to isometric handgrip exercise

    Time frame: Before and after 9 weeks of androgen deprivation therapy or placebo

  4. Change in ambulatory blood pressure variability

    Ambulatory systolic blood pressure variability will be determined from 24-hour ambulatory blood pressure monitoring using the standard deviation of blood pressure readings

    Time frame: Before and after 9 weeks of androgen deprivation therapy or placebo

  5. Change in beat-to-beat blood pressure variability

    Beat-to-beat systolic blood pressure variability will be determined using the standard deviation of blood pressure readings from finger photoplethysmography measured in the laboratory.

    Time frame: Before and after 9 weeks of androgen deprivation therapy or placebo

  6. Change in renal vascular resistance

    Renal blood flow will be determined using ultrasound and blood pressure will be determined using finger photoplethysmography. These measures will be used to estimate renal vascular resistance.

    Time frame: Before and after 9 weeks of androgen deprivation therapy or placebo

  7. Change in kidney injury biomarkers

    Neutrophil gelatinase-associated lipocalin (NGAL), tissue inhibitor of metalloproteinases 2 (TIMP2), and insulin-like growth factor binding protein 7 (IGFBP7) will be quantified in urine using commercially available assay kits. Concentrations will be normalized to urinary flow rate.

    Time frame: Before and after 9 weeks of androgen deprivation therapy or placebo

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2028, 23 months after the start.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 30, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2030
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
50→60
Nov 2, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Nov 2, 2026
    Enrollment 50→60
    + 1 other change: verification date
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848828
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Aug 1, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2030 (estimated)
Last update
Nov 2, 2026

Study contacts

Matthew Babcock, PhD
Contact
babcockmc@vcu.edu
‪(804) 396-4718‬
Matthew Babcock, PhD
principal investigator · Virginia Commonwealth University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gonadotropin-Releasing Hormone

Start the discussion